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1 | INTRODUCTION  
 
Over the past decades, multiparameter flow cytometry has become 
the method of choice for the differential diagnosis of several hema- 
tological diseases, for the definition of prognostic factors, and for the 
identification of rare cell populations in peripheral blood (PB) and bone 
marrow samples (BM).1-6 
Flow cytometry, through the presence or absence of specific sur- 
face antigens, detects abnormal cells and helps in identifying their 
lineage and maturation stage, detects abnormal cells through identifi- 
cation of antigen expression that differs from the normal. The wider ap- 
plication of flow cytometry in diagnostic and research fields increases 
the need to distinguish between real and artifact positive signals given 
that antigen-antibody interactions, characterized by weak bindings, 
may involve unexpected molecules. The presence of dead cells, cell 
doublets, and the nonspecific antibody binding can compete to gen- 
erate artifacts in the phenotype. In some cases, an antibody can bind 
similar antigens not of interest or an epitope can be shared by different 
antigens or the Fc of many antibodies can be bound by Fc-receptors 
expressed by different cells of the immune system.7 Undesired anti- 
body’s binding depends not only on the antibody’s specificity but also 
on a wide variety of other interactions, as well as the physical and bi- 
ological conditions that the target cell population encountered during 
the assay. 
The ability to reliably distinguish between positive and negative 




Introduction: Flow cytometry is a useful tool for diagnosis and minimal residual dis- 
ease (MRD) study of hematological diseases. Standard sample preparation protocols 
are characterized by stain-lyse-wash (SLW). To prevent nonspecific bindings and 
achieve high sensitivity in MRD studies, lyse-wash-stain-wash (LWSW) is required. To 
our knowledge, no comparison between the two methods has been performed. 
Methods: We compared mean fluorescence intensity (MFI), stain index, signal-to- 
noise ratio, and percentage of positive cells of 104 antibodies and of 13 selected anti- 
bodies tested in 10 samples simultaneously prepared with the two methods. 
Results: MFI and percentages of positive cells obtained by the two methods did not 
show significant differences and showed a very high correlation. Stain index and 
signal-to-noise ratio presented higher values for kappa and lambda surface chains in 
LWSW samples and a trend of higher values for the other antibodies in SLW 
samples. 
Conclusions: We suggest to use LWSW method also at diagnosis to obtain more 
comparable antibody intensity expressions when samples from the same patient are 
processed for MRD evaluation after bulk lysis. Moreover, LWSW can prevent 
nonspecific bindings, shows no differences in the identification and quantitation of the 
populations of interest, and reduces acquisition of cell debris. 
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 Sample preparation is a key phase to prevent nonspecific bindings 
or artifacts. Washing samples with a saline solution added with albu- 
min before staining or treating them with Fc-block reagents reduce 
interferences in antibody binding.8 
A large number of guidelines suggest as standard preparation 
protocols for the immunophenotype study the stain-lyse-wash (SLW) 
methods to obtain best signal discrimination.9-17 However, many 
reports on minimal residual disease (MRD) studies by flow cytome- 
try18-22 recommend a bulk lysis of the sample, which consists on the 
lysis of a high number of cells in PB or BM samples followed by wash- 
ing and staining to increase sensitivity. 
In this study, we compared the mean fluorescence intensity (MFI), 
stain index, signal-to-noise ratio, and percentages of positive cells 
tested with 104 surface antibodies before (SLW) and after lyse and 
wash (LWSW). Moreover, we compared the above-mentioned param- 
eters with 13 selected antibodies used to identify monocyte and lym- 
phocyte subpopulations. 
 
2 | MATERIALS AND METHODS 
 
2.1 | Samples collection 
From August 2015 to January 2016, a total of 15 PB and 5 BM sam- 
ples, collected in vacutainers containing EDTA (Becton Dickinson (BD) 
San Josè, California, USA), were obtained from patients sent to our 
laboratory for routine flow cytometry analysis and tested. 
 
2.2 | Ethics statement 
The data collection and additional analyses, such as statistical tests, 
were performed anonymously. This study was carried out in accord- 
ance with Declaration of Helsinki and subsequent amendments. 
 
2.3 | Lyse-wash-stain-wash (LWSW) procedure 
1 × 106 of bone marrow cells or 100 μL of peripheral blood is incu- 
bated in the darkness at room temperature (RT) for 10 minutes with 
3 mL of NH4Cl lysing solution (pH 7.3), centrifuged at 4°C for 5 min- 
utes at 500 g. The supernatant is discarded and the sample washed in 
3 mL of phosphate saline buffer solution (PBS) + bovine serum albu- 
min (BSA) 0.5% and sodium azide 0.1% (1 mol L−1), stained with the 
appropriate amount of antibodies in darkness at RT for 15 minutes 
and washed in PBS-BSA. 
 
2.4 | Stain-lyse-wash (SLW) procedure 
1 × 106 of bone marrow cells or 100 μL of peripheral blood is stained 
with the appropriate amount of antibodies in the darkness at RT for 
15 minutes, incubated in the darkness at RT for 10 minutes with 3 mL 
of NH4Cl, centrifuged at 4°C for 5 minutes at 500 g. The supernatant 
is discarded and the sample is washed in PBS-BSA. 
Mean fluorescence intensity (MFI), stain index, signal-to-noise 
ratio, and percentages of positive cells were assessed by correlating 
the population positive for a given antibody with white blood cells in 
the sample gated by physical cytometric parameters. 
To compare the 2 preparation methods, the same amount of anti- 
bodies was employed, and the same compensation was applied. 
The 104 antibodies were studied as single reagent in a total of 
five BM and five PB samples for one replicate for each reagent. Their 
fluorochromes, clones, manufacturers, and SLW/LWSW MFI ratio are 
reported in Table 1. 
A 100.000 total events for each sample were acquired with Navios 
flow-cytometer Beckmann Coulter (BC) and data analysis was per- 
formed with Kaluza software (BC). 
Unstained cells and single fluorochrome stained cells were used 
to set the instrument. Instrument performance was checked daily by 
recording fluorescence intensity with calibrating beads (Flow-Check 
Pro Fluorospheres BC, Beckman Coulter). 
Moreover, 10 peripheral blood samples treated with both methods 
were tested with the following selected antibodies: CD45 krome or- 
ange (KO), CD14 phycoerythrin cyanine 5.5 (PC 5.5), HLA-DR fluores- 
cein isothiocyanate (FITC), CD3 phycoerythrin cyanine 7 (PC-7), CD4 
pacific blue (PB), CD8 allophycocyanin (APC), CD16 + CD56 phyco- 
erythrin (PE), CD19 PC-7, CD20 APC-Alexa Fluor 750, CD5 PB, CD10 
PC5.5 (BC), Lambda PE, Kappa FITC (DAKO). 
In the analysis, the first step was to select white blood cells with- 
out debris by a FSC/SSC dot plot. The population well separated by all 
other cells, with a positive signal for an antigen (more than 10log of 
positivity), is selected as described in Figure 1. 
The arithmetic MFI of each event for a given antibody was cal- 
culated by Kaluza software after the selection of the positive cell 
population. 
Signal-to-noise ratio was calculated as follows: MFI of positive 
peak/MFI of negative peak and stain index as (MFI of positive peak 
- MFI of negative peak)/2*standard deviation of negative peak. 
 
 
2.5 | Statistical analysis 
Differences between means were studied by T test; correlation be- 
tween results was assessed by Pearson product-moment correlation 




3 | RESULTS 
 
Means of MFI and of percentages of positive cells obtained by the 
two methods were not significantly different: mean MFI of SLW and 
LWSW were 27 and 29, respectively (P = .224), while mean % of SLW 
and LWSW were 20.4% and 20.7% (P = .186), respectively. 
MFI and percentages obtained by the two methods showed a 
statistically significant correlation: r2 = 0.83 P < .001 and r2 = 0.99  
P < .001, respectively (Figure 2A and B). 
The Figure 2A shows some antibodies with a MFI higher in 
LWSW than in SLW samples (indicated as white circles) that were  







TABLE 1 Antibodies, fluorochromes, and clones tested in the study   
Antibody Fluorochrome Company Clone SLW/LWSW MFI Antibody Fluorochrome Company Clone SLW/LWSW MFI   
CD25 APC BC B9E9 0.03 CD4 PB BC 13B8.2 1   
CD235a PE DAKO SC159 0.04 CD33 PE BC 906 1   
CD235a FITC DAKO JC159 0.05 CD4 FITC DAKO MT310 1.01   
Kappa/Lambda FITC/PE DAKO Polyclonal 0.35/0.16 CD117 APC CYTOGNOS 104D2 1.01   
CD14 PC5.5 BC RM052 0.36 CD64 PB BC 22 1.03   
CD11b APC BD D12 0.42 CD43 FITC DAKO DF-T1 1.03   
CD23 PC-7 BD M-L233 0.47 CD8 APC BC SK1 1.04   
CD66 FITC SANQUIN CLB-B13.9 0.49 CD45 APC-H7 BD 2D1 1.05   
CD71 APC BD L01.1 0.55 CD5 PB BC BL1a 1.05   
CD15 PerCP-Cy5.5 BD HI98 0.56 CD38 PC-7 BD HB7 1.05   
CD52 PE INVITROGEN CF1D12 0.57 CD20 APC-A700 BC B9E9 1.06   
CD33 FITC BC D3HL60.251 0.6 CD14 APC BD Mϕ P9 1.07   
CD13 PE BC SJ1D1 0.64 CD20 PC-7 BD L27 1.07   
CD38 APC-A750 BC LS198-4-3 0.67 CD200 APC-A750 BC OX-104 1.11   
CD20 PE DAKO B-LY1 0.69 CD4 PC7 BD SK3 1.13   
CD10 PC5.5 BC ALB1 0.71 CD45 V450 BD HI30 1.13   
CD16 PerCP-Cy5.5 BD 3G8 0.74 CD8 PC-7 BD SK1 1.14   
CD14 FITC DAKO TϋK4 0.74 CD22 PE BD S-HCL-1 1.16   
CD14 PC-7 BD M5E2 0.76 CD3 V450 BD UCHT1 1.17   
CD138 PB BC B-A38 0.77 CD8 PerCP BD SK1 1.17   
CD64 FITC BIOLEGEND 10.1 0.79 CD20 APC-A750 BC B9E9 1.17   
CD138 PC5.5 BC B-A38 0.82 CD14 APC-H7 BD Mϕ P9 1.18   
CD33 PC5.5 BC D3HL60.251 0.83 CD34 FITC DAKO BIRMA-K3 1.2 
  
CD10 APC BD HI10a 0.84 CD71 FITC DAKO Ber-T9 1.2 
  
CD33 APC BC D3HL60.251 0.84 CD20 FITC BD L27 1.22 
  
CD4 APC-H7 BD SK3 0.84 CD45 APC BD 2D1 1.24 
  
CD22 FITC BD S-HCL-1 0.85 CD4 PerCP-Cy5.5 BD SK3 1.26 
  
CD34 APC BC 581 0.86 CD71 APC-A700 BC YDJ1.2.2 1.26 
  
CD45 KO BC J.33 0.88 CD5 PC-7 BD L17F12 1.29 
  
CD79B PE DAKO SN8 0.88 CD34 PC-7 BD 8G12 1.29 
  
CD16 PE BC 3G8 0.9 HLA-DR PE DAKO AB3 1.3 
  












Antibody Fluorochrome Company Clone SLW/LWSW MFI Antibody Fluorochrome Company Clone SLW/LWSW MFI  
CD59 PE INVITROGEN MHCD5904 0.9 CD20 PerCP-Cy5.5 BD L27 1.33  
CD4 V450 BD RPA-T4 0.9 CD22 PC5.5 BC SJ10.1H11 1.33  
CD38 APC BC LS198-4-3 0.92 CD71 APC-H7 BD M-A712 1.37  
CD5 FITC BC BL1a 0.92 CD15 PE BC 80H5 1.38  
HLA-DR APC BC IMMU-357 0.93 CD19 APC BC J3-119 1.4   
CD45 V500 BD HI30 0.94 CD3 APC IMMUNOSTEP 145-2C11 1.4   
CD56 PE BC N901 0.95 CD45 PerCP-Cy5.5 BD 2D1 1.42   
CD117 PE CYTOGNOS 104D2 0.95 CD3 PE DAKO UCHT1 1.44     
HLA DR FITC BC B8.12.2 0.96 CD14 PE DAKO TϋK4 1.44     
CD138 APC BD MI15 0.96 CD138 FITC CYTOGNOS B-A38 1.52     
CD3 FITC DAKO UCHT1 0.97 CD8 APC-H7 BD SK1 1.52     
CD38 PB BC LS198-4-3 0.97 CD5 PE BC BL1a 1.53     
CD5 PC5.5 BC BL1a 0.97 CD34 PE BD 8G12 1.54     
CD20 APC BC B9E9 0.97 CD3 PC7 BC UCHT1 1.58     
CD55 PE Southern 143-30 0.99 CD23 PE DAKO MHM6 1.59     
  Biotech            
CD56 APC BC N901 0.99 CD24 PE BD ML5 1.61     
CD56 V450 BD B159 1 CD33 PC-7 BD P67.6 1.86     
CD19 PB BC J3-119 1 CD2 PC-7 BC 39C1.5 1.89     
CD19 PC-7 BC J3-119 1 CD45 PB DAKO T29/33 2.47     
 
  
BD: Becton Dickinson (San Josè, CA, USA); BC: Beckman Coulter (Brea, CA, USA); BIOLEGEND (San Diego, CA, USA); CYTOGNOS (Salamanca, Spain); DAKO (Golstrup, Denmark); IMMUNOSTEP (Salamanca, 
Spain); INVITROGEN (Waltham, MA, USA); SANQUIN (Amsterdam, The Nederlands); Southern Biotech (Birmingham, AL, USA). 
APC, allophycocyanin; APC-A700, allophycocyanin-alexa 700; APC-A750, allophycocyanin-alexa 750; FITC, fluorescein isothiocyanate; KO, krome orange; PB, pacific blue; PC5.5, phycoerythrin cyanine 5.5; 
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FIGURE  2  Linear regression of MFI and percentages values of 
104 antibodies in samples simultaneously prepared with LWSW and 
SLW methods. (A) Linear regression of MFI values of 104 antibodies 
in samples simultaneously prepared with LWSW and SLW methods. 
White circles represent samples with visible higher MFI in LWSW 
than in SLW samples. White squares represent samples with visible 
higher MFI in SLW than in LWSW samples. (B) Linear regression 
of percentage of cells positive for 104 antibodies in samples 








FIGURE 1 Gating strategy and exemplificative dot plots. (A) 
physical parameters obtained by the two methods. (B) antibody with 
similar MFI obtained by the two methods. (C) antibody with higher 
MFI obtained by SLW than LWSW method. (D) antibody with higher 
MFI obtained by LWSW than SLW method 
 
 
CD11b APC, and CD71 APC, while the antibodies with higher MFI in 
SLW than LWSW sample were CD57 FITC and CD14 PE (indicated  
as white squares). 
Bland-Altman analysis of percentages of positive cells showed 
mean difference of −0.20 with standard deviation of 2.04, and all dif- 
ferences between SLW and LWSW values were within a range of ±5% 
(Figure 3). 
Bland-Altman analysis of MFI of positive cells showed mean of 
differences of −2.14 with standard deviation of 17.9 (data not shown). 
Signal-to-noise ratio and stain index were higher in SLW than 
LWSW samples (59.8 vs 41.7 P < .001, 24.4 vs 17.8 P = .001, 
respectively). 
Means of debris obtained by SLW (31.8%) and LWSW (19.3%) 
were significantly different P < .001) (Figure 4). 
Analysis of 13 selected antibodies tested in 10 samples showed: 
 
• no statistical significant differences in the percentages of positive 
cells; 
• higher MFI for CD3 (means: 30.6 vs 23.6 P < .01) in SLW than 
LWSW samples and for HLA-DR (means: 12.3 vs 27.1 P < .05), 
CD16 + 56 (means: 74.4 vs 123.6 P < .01) in LWSW than SLW 
samples; 
• higher signal-to-noise ratio in SLW samples for CD45 (means: 51.6 
vs 36.6 P < .05), CD3 (means: 230.8 vs 36.9 P < .05), CD19 (means: 
92.8 vs 46.8 P < .01), and CD10 (means: 49.7 vs 20.6 P < .01); 
• higher stain index in SLW than LWSW samples for CD3 (means: 
57.9 vs 20.2 P < .01), CD19 (means: 30.1 vs 20.9 P < .01), and 
CD10 (means: 28.4 vs 14.81 P < .01); 






































FIGURE  3     Bland-Altman  analysis 
of percentages of cells positive for 104 
antibodies in samples simultaneously 



















FIGURE 4 Percentages of debris obtained in LWSW and SLW 
samples 
 
for surface kappa and lambda chains (means MFI: kappa LWSW 
18.9 vs kappa SLW 7.4 P < .05; lambda LWSW 30.8 vs lambda SLW 
2.1 P < .01; means stain index: kappa LWSW 8.8 vs kappa SLW 4.2 
P < .01; lambda LWSW 14.6 vs lambda SLW 7.6 P < .05, means 
signal-to-noise ratio: kappa LWSW 22 vs kappa SLW 7.6 P < .05; 




4 | CONCLUSION  
 
Different methods to prepare samples for flow cytometry analysis 
have been described in a high number of study groups, and the SLW 
method is considered the standard one, because it provides the best 
signal output. However, in the antigen-antibody interactions, some 
difficulties can occur for the interactions with similar epitopes or for 
the interferences of different cells of immune system that can bind 
the Fc with a specific Fc-receptor.7 A solution for this problem, in par- 
ticular for the study of surface kappa and lambda chains, is offered 
by some study groups that recommended the sample washing with 
PBS added with BSA to remove interfering free extracellular immu- 
noglobulins23 or to avoid artifacts of cytophilic antibodies.9 Therefore, 
lyse and wash of a sample before staining, as in LWSW method,  
can prevent artifacts and, in MRD studies, allows to obtain a higher 
 
number of cells. To our knowledge, no comparison between these 
two methods has been described and it is not known whether a sec- 
ond wash gives significant differences in terms of antigens’ binding 
and expression. We compared the expression of 104 antibodies as- 
sessed by both SLW and LWSW to identify differences between the 
two methods. Samples prepared with both methods did not show sig- 
nificant differences in terms of percentage and MFI of positive cells 
even though stain index and signal-to-noise ratio were significantly 
higher in SLW than LWSW samples. The antibodies with higher MFI 
in LWSW method, indicated as white circles in Figure 2A (CD235a 
FITC, CD235a PE, CD25 APC, CD14 PC5.5, CD11b APC, and CD71 
APC), showed an MFI increase that overcame the slight increase of 
background. In two cases, indicated as white squares (CD57 FITC and 
CD14 PE), this phenomenon was observed in SLW samples. Moreover, 
the LWSW method increased both the intensity of background and of 
positive signal, but the stain index was reduced because the back- 
ground exceeded the signal. However, the selection of positive cell 
populations was not affected by these differences, and no different 
percentages were obtained. 
Mean of differences between SLW and LWSW percentages was 
−0.20, and all differences were within a range of ±5%. Moreover, SLW 
samples presented a significantly higher percentage of debris than 
LWSW samples that determined higher number of “useful events” 
with the same threshold setup. 
We also analyzed the expression of 13 selected antibodies in 10 
samples prepared with the two methods. No significant difference in 
terms of percentage of positive cells was observed and, except for sur- 
face kappa and lambda chains, all other antibodies have shown higher 
values of stain index and signal-to-noise ratio in SLW samples than 
LWSW. 
Despite the high concordance of MFI between the two methods, 
the signal-to-noise ratios and the stain indexes obtained, confirmed 
that SLW gave the best signal discrimination as reported by some 
guidelines9-17 and that the expression of kappa and lambda surface 
immunoglobulins became brighter after sample washing.24 
However, to achieve a high sensitivity for MRD evaluation, LWSW 
should be performed as suggested by the Euroflow consortium.22 
We suggest the use of LWSW also in samples from newly diag- 
nosed patients because, despite differences in stain index and signal- 


















 methods. Moreover, the use of the same method to stain cells from a 
patient at diagnosis and throughout the follow-up is recommended, to 
obtain more comparable cell parameters. Finally, LWSW, through the 
sample wash before the staining, prevents artifacts which may occur 
also in fresh samples and allows to acquire a higher number of useful 
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